{"id":34804,"date":"2025-08-05T10:31:33","date_gmt":"2025-08-05T08:31:33","guid":{"rendered":"https:\/\/ggba.swiss\/?p=34804"},"modified":"2025-08-05T10:31:35","modified_gmt":"2025-08-05T08:31:35","slug":"oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/","title":{"rendered":"Oculis secures up to CHF 100 million in expanded loan facility with BlackRock"},"content":{"rendered":"\n<p>Vaud-based biopharmaceutical company <a href=\"https:\/\/oculis.com\/\">Oculis<\/a> has announced an amended loan agreement with <a href=\"https:\/\/www.blackrock.com\/corporate\">BlackRock<\/a>, expanding its borrowing capacity from CHF 75 million to up to CHF 100 million. This upsized structure strengthens the company\u2019s financial runway through early 2028, supporting ongoing development of its late-stage ophthalmic and neuroprotective treatments.<\/p>\n\n\n\n<p>The revised agreement replaces a prior deal signed in May 2024 and comprises three tranches of CHF 25 million each, along with an optional fourth tranche of up to CHF 25 million, subject to mutual agreement. No funds were drawn at signing, but the structure offers Oculis enhanced flexibility as it moves closer to several clinical and regulatory milestones.<\/p>\n\n\n\n<p>The company is progressing with three core product candidates :<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>OCS-01, a topical eye drop for diabetic macular edema, is currently in Phase 3 DIAMOND trials. Topline results are expected in Q2 2026, followed by a potential NDA filing later that year.<\/li>\n\n\n\n<li>Privosegtor (OCS-05), a neuroprotective therapy, is preparing for regulatory discussions across three indications: acute optic neuritis, NAION, and multiple sclerosis relapses.<\/li>\n\n\n\n<li>Licaminlimab (OCS-02), an anti-TNF\u03b1 eye drop for dry eye disease, will begin Phase 2\/3 trials in the second half of 2025.<\/li>\n<\/ul>\n\n\n\n<p>\u201cOur current robust cash position provides runway into early 2028, which is further strengthened by the loan facility, as we remain focused on advancing our portfolio of differentiated assets,\u201d said Riad Sherif, M.D., CEO of Oculis.<\/p>\n\n\n\n<p>This latest financing development follows two major equity rounds over the past 18 months: a <a href=\"https:\/\/ggba.swiss\/en\/oculis-announces-completion-of-oversubscribed-usd-59-million-registered-direct-offering\/\">USD 59 million registered offering in April 2024<\/a> and <a href=\"https:\/\/ggba.swiss\/en\/oculis-secures-usd-100-million-to-advance-its-neuroprotective-treatment-pipeline\/\">an oversubscribed USD 100 million raise in February 2025<\/a>. Together, these milestones underscore strong investor confidence in Oculis\u2019s clinical pipeline and strategic vision.<\/p>\n\n\n\n<p>Headquartered in Lausanne and operating in the US and Iceland, Oculis is publicly traded and dual-listed on NASDAQ and NASDAQ Iceland.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Oculis expands its loan facility with BlackRock to CHF 100 million, extending its financial runway and supporting late-stage clinical trials.<\/p>\n","protected":false},"author":6,"featured_media":34805,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,894,902],"class_list":["post-34804","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-financing","tag-personalized-medicine"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oculis secures up to CHF 100M in expanded loan facility | GGBa<\/title>\n<meta name=\"description\" content=\"Oculis expands its loan facility with BlackRock to CHF 100 million, extending its financial runway and supporting late-stage clinical trials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oculis secures up to CHF 100M in expanded loan facility | GGBa\" \/>\n<meta property=\"og:description\" content=\"Oculis expands its loan facility with BlackRock to CHF 100 million, extending its financial runway and supporting late-stage clinical trials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-05T08:31:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-05T08:31:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Oculis-Eye-Care-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Oculis secures up to CHF 100 million in expanded loan facility with BlackRock\",\"datePublished\":\"2025-08-05T08:31:33+00:00\",\"dateModified\":\"2025-08-05T08:31:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/\"},\"wordCount\":292,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Oculis-Eye-Care-1180x811-1.jpg\",\"keywords\":[\"Biotech\",\"Financing\",\"Personalized Medicine\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/\",\"url\":\"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/\",\"name\":\"Oculis secures up to CHF 100M in expanded loan facility | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Oculis-Eye-Care-1180x811-1.jpg\",\"datePublished\":\"2025-08-05T08:31:33+00:00\",\"dateModified\":\"2025-08-05T08:31:35+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Oculis expands its loan facility with BlackRock to CHF 100 million, extending its financial runway and supporting late-stage clinical trials.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Oculis-Eye-Care-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Oculis-Eye-Care-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"Oculis\u2019 pipeline aims to bring non-invasive, transformative therapies to patients suffering from vision-threatening and neuro-ophthalmic conditions with limited treatment options.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oculis secures up to CHF 100 million in expanded loan facility with BlackRock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oculis secures up to CHF 100M in expanded loan facility | GGBa","description":"Oculis expands its loan facility with BlackRock to CHF 100 million, extending its financial runway and supporting late-stage clinical trials.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/","og_locale":"en_US","og_type":"article","og_title":"Oculis secures up to CHF 100M in expanded loan facility | GGBa","og_description":"Oculis expands its loan facility with BlackRock to CHF 100 million, extending its financial runway and supporting late-stage clinical trials.","og_url":"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2025-08-05T08:31:33+00:00","article_modified_time":"2025-08-05T08:31:35+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Oculis-Eye-Care-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Oculis secures up to CHF 100 million in expanded loan facility with BlackRock","datePublished":"2025-08-05T08:31:33+00:00","dateModified":"2025-08-05T08:31:35+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/"},"wordCount":292,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Oculis-Eye-Care-1180x811-1.jpg","keywords":["Biotech","Financing","Personalized Medicine"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/","url":"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/","name":"Oculis secures up to CHF 100M in expanded loan facility | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Oculis-Eye-Care-1180x811-1.jpg","datePublished":"2025-08-05T08:31:33+00:00","dateModified":"2025-08-05T08:31:35+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Oculis expands its loan facility with BlackRock to CHF 100 million, extending its financial runway and supporting late-stage clinical trials.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Oculis-Eye-Care-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2025\/08\/Oculis-Eye-Care-1180x811-1.jpg","width":1180,"height":811,"caption":"Oculis\u2019 pipeline aims to bring non-invasive, transformative therapies to patients suffering from vision-threatening and neuro-ophthalmic conditions with limited treatment options."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/oculis-secures-up-to-chf-100-million-in-expanded-loan-facility-with-blackrock\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Oculis secures up to CHF 100 million in expanded loan facility with BlackRock"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/34804","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=34804"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/34804\/revisions"}],"predecessor-version":[{"id":34808,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/34804\/revisions\/34808"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/34805"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=34804"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=34804"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=34804"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}